Vertex Pharmaceuticals, Inc., an international biotech company that has recently been making significant progress in clinical phase research geared towards combating cystic fibrosis, has just announced that they will be presenting during the UBS Global Healthcare Conference.
The conference is scheduled to take place at the Sheraton New York Hotel on May 19-21, with Vertex’s presentation scheduled on Tuesday, May 20 at 11:00 AM ET. This three-day convention has as its attendees key investors and more than 200 companies, ready to conduct their own presentations, small lectures, and one-on-one forums.
It is anticipated that Vertex will offer further insight into their ongoing cystic fibrosis related clinical trials, which are expected to offer critical data and conclusions later in the year. Vertex was recently featured on Cystic Fibrosis News for their exploratory form of Kalydeco, otherwise known as VX-661. The drug, if found to be both safe and effective, could offer a wider range of the CF patent population with a viable, new treatment for the disease.
The invitees and participants come from the following wide array of specialized sectors of biotechnology: Alternate Site, Biotechnology, Diagnostics, Distribution, Healthcare REITs, Home Care, Hospitals, Information Technology, Laboratory Services, Life Sciences Tools, Long-Term Care, Managed Care, Medical Technology, Pharmaceuticals, Pharmaceutical Services, Social Services, Specialty Pharmaceuticals and Staffing.
For those interested in Vertex’s presentation, but cannot make it to the conference, you may stream the session’s audio live through the company’s website. Simply access the “Investors” portion under the “Events and Presentations” tab. Note that you must log in to the audio streaming at least 15 minutes before the presentation is scheduled to begin in order to ensure a prompt feed. However, in case you miss the live stream or would wish to listen to it again, the audio webcast will be archived online until 2 weeks after the presentation.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?